Genetic vaccine for tuberculosis (pVAXhsp65) primes neonate mice for a strong immune response at the adult stage
2007

Genetic Vaccine for Tuberculosis Primes Neonate Mice for Strong Immune Response

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): Pelizon Ana Cláudia, Martins Douglas R, Zorzella Sofia FG, Trombone Ana Paula F, Lorenzi Júlio CC, Carvalho Robson F, Brandão Izaíra T, Coelho-Castelo Arlete AM, Silva Célio L, Sartori Alexandrina

Primary Institution: São Paulo State University (UNESP)

Hypothesis

Can a genetic vaccine containing hsp65 from Mycobacterium leprae effectively prime the immune response in neonate mice against tuberculosis?

Conclusion

The genetic vaccine pVAXhsp65 can safely prime the immune system of neonate mice for a strong immune response later in life.

Supporting Evidence

  • The vaccine was transcribed by muscular cells of neonate mice without integration into the cellular genome.
  • pVAXhsp65 and BCG were equally able to prime newborn mice for a strong immune response.
  • Priming with pVAXhsp65 did not induce tolerance in neonate mice.

Takeaway

This study shows that a special vaccine can help baby mice build a strong defense against tuberculosis when they grow up.

Methodology

Neonate mice were immunized with the pVAXhsp65 vaccine and later evaluated for immune response through antibody and cytokine production.

Limitations

The study primarily focused on neonate mice, and results may not directly translate to human infants.

Participant Demographics

BALB/c mice, aged 5 days at the start of the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-0556-5-12

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication